|
1
|
Ross R and Agius L: The process of
atherogenesis-cellular and molecular interaction: From experimental
animal models to humans. Diabetologia. 35(Suppl 2): S34–S40. 1992.
View Article : Google Scholar
|
|
2
|
Wang JC and Bennett M: Aging and
atherosclerosis: Mechanisms, functional consequences and potential
therapeutics for cellular senescence. Circ Res. 111:245–259. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ross R: Atherosclerosis-an inflammatory
disease. New Engl J Med. 340:115–126. 1999. View Article : Google Scholar
|
|
4
|
Owens GK: Regulation of differentiation of
vascular smooth muscle cells. Physiol Rev. 75:487–517.
1995.PubMed/NCBI
|
|
5
|
Heldin CH and Westermark B: Mechanism of
action and in vivo role of platelet-derived growth factor. Physiol
Rev. 79:1283–1316. 1999.PubMed/NCBI
|
|
6
|
Peiser L and Gordon S: The function of
scavenger receptors expressed by macrophages and their role in the
regulation of inflammation. Microbes Infect. 3:149–159. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whelan FJ, Meehan CJ, Golding GB, McConkey
BJ and Bowdish DM: The evolution of the class A scavenger
receptors. BMC Evol Biol. 12:227–237. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Hu G, Chen D, Gong AY, Soori GS,
Dobleman TJ and Chen XM: Suppression of SCARA5 by Snail1 is
essential for EMT-associated cell migration of A549 cells.
Oncogenesis. 2:e732013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan N, Zhang S, Yang Y, Cheng L, Li C, Dai
L, Dai L, Zhang X, Fan P, Tian H, et al: Therapeutic upregulation
of Class A scavenger receptor member 5 inhibits tumor growth and
metastasis. Cancer Sci. 103:1631–1639. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang J, Zheng DL, Qin FS, Cheng N, Chen
H, Wan BB, Wang YP, Xiao HS and Han ZG: Genetic and epigenetic
silencing of SCARA5 may contribute to human hepatocellular
carcinoma by activating FAK signaling. J Clin Invest. 120:223–241.
2010. View
Article : Google Scholar :
|
|
11
|
Auclair S, Milenkovic D, Besson C, Chauvet
S, Gueux E, Morand C, Mazur A and Scalbert A: Catechin reduces
atherosclerotic lesion development in apo E-deficient mice: A
transcriptomic study. Atherosclerosis. 204:e21–e27. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chadjichristos CE, Morel S, Derouette JP,
Sutter E, Roth I, Brisset AC, Bochaton-Piallat ML and Kwak BR:
Targeting connexin 43 prevents platelet-derived growth
factor-BB-induced phenotypic change in porcine coronary artery
smooth muscle cells. Circ Res. 102:653–660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Andrés V: Control of vascular cell
proliferation and migration by cyclin-dependent kinase signalling:
New perspectives and therapeutic potential. Cardiovasc Res.
63:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Syväranta S, Alanne-Kinnunen M, Oörni K,
Oksjoki R, Kupari M, Kovanen PT and Helske-Suihko S: Potential
pathological roles for oxidized low-density lipoprotein and
scavenger receptors SR-AI, CD36 and LOX-1 in aortic valve stenosis.
Atherosclerosis. 235:398–407. 2014. View Article : Google Scholar
|
|
16
|
Raines EW: PDGF and cardiovascular
disease. Cytokine Growth Factor Rev. 15:237–254. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abe J, Deguchi J, Takuwa Y, Hara K, Ikari
Y, Tamura T, Ohno M and Kurokawa K: Tyrosine phosphorylation of
platelet derived growth factor beta receptors in coronary artery
lesions: Implications for vascular remodelling after directional
coronary atherectomy and unstable angina pectoris. Heart.
79:400–406. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jawien A, Bowen-Pope DF, Lindner V,
Schwartz SM and Clowes AW: Platelet-derived growth factor promotes
smooth muscle migration and intimal thickening in a rat model of
balloon angioplasty. J Clin Invest. 89:507–511. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bilder G, Wentz T, Leadley R, Amin D, Byan
L, O'Conner B, Needle S, Galczenski H, Bostwick J, Kasiewski C, et
al: Restenosis following angioplasty in the swine coronary artery
is inhibited by an orally active PDGF-receptor tyrosine kinase
inhibitor, RPR101511A. Circulation. 99:3292–3299. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lannoy M, Slove S, Louedec L, Choqueux C,
Journé C, Michel JB and Jacob MP: Inhibition of ERK1/2
phosphorylation: A new strategy to stimulate elastogenesis in the
aorta. Hypertension. 64:423–430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mii S, Khalil RA, Morgan K, Ware JA and
Kent KC: Mitogen-activated protein kinase and proliferation of
human vascular smooth muscle cells. Am J Physiol. 270:H142–H150.
1996.PubMed/NCBI
|
|
22
|
Nomiyama T, Nakamachi T, Gizard F, Heywood
EB, Jones KL, Ohkura N, Kawamori R, Conneely OM and Bruemmer D: The
NR4A orphan nuclear receptor NOR1 is induced by platelet-derived
growth factor and mediates vascular smooth muscle cell
proliferation. J Biol Chem. 281:33467–33476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goncharova EA, Ammit AJ, Irani C, Carroll
RG, Eszterhas AJ, Panettieri RA and Krymskaya VP: PI3K is required
for proliferation and migration of human pulmonary vascular smooth
muscle cells. Am J Physiol Lung Cell Mol Physiol. 283:L354–L363.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi KH, Kim JE, Song NR, Son JE, Hwang
MK, Byun S, Kim JH, Lee KW and Lee HJ: Phosphoinositide 3-kinase is
a novel target of piceatannol for inhibiting PDGF-BB-induced
proliferation and migration in human aortic smooth muscle cells.
Cardiovasc Res. 85:836–844. 2010. View Article : Google Scholar
|
|
25
|
Lipson KE, Pang L, Huber LJ, Chen H, Tsai
JM, Hirth P, Gazit A, Levitzki A and McMahon G: Inhibition of
platelet-derived growth factor and epidermal growth factor receptor
signaling events after treatment of cells with specific synthetic
inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp
Ther. 285:844–852. 1998.PubMed/NCBI
|
|
26
|
Myllärniemi M, Frösen J, Ramirez LG,
Buchdunger E, Lemström K and Häyry P: Selective tyrosine kinase
inhibitor for the platelet-derived growth factor receptor in vitro
inhibits smooth muscle cell proliferation after reinjury of
arterial intima in vivo. Cardiovasc Drug Ther. 13:159–168. 1999.
View Article : Google Scholar
|
